Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.

Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Fountzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G
Clin Cancer Res. 2009 15 (19): 6258-66

PMID: 19789313 · DOI:10.1158/1078-0432.CCR-08-1867

MeSH Terms (23)

Adult Aged Aged, 80 and over Antineoplastic Agents Benzamides Biomarkers, Tumor Brain Neoplasms Extracellular Signal-Regulated MAP Kinases Female Glioblastoma Humans Imatinib Mesylate Ki-67 Antigen Male Middle Aged Neoadjuvant Therapy Oncogene Protein v-akt Piperazines Proto-Oncogene Proteins c-kit Pyrimidines Receptors, Platelet-Derived Growth Factor Signal Transduction Young Adult

Connections (1)

This publication is referenced by other Labnodes entities: